A Comparison of 2 Disease Burden Assessment Methods (3D Volume Versus the Number of Lesions) for Prognostication of Survival in Metastatic Melanoma: Implications for the Characterization of Oligometastatic Disease
Jina Kim(Ajou University), Robert Olson(BC Cancer Agency), Jee Suk Chang(Yonsei University), Tae Hyung Kim(Yonsei University), Kyung Hwan Kim(Yonsei University), Jin Sung Kim(Yonsei University), Heejoo Ko(Catholic University of Korea), Sang Joon Shin(Yonsei University), Jin Sung Kim(Yonsei University), Jina Kim(Yonsei University), Kyung Hwan Kim(Yonsei University), Seo Hee Choi(Yonsei University), Mitchell Liu, Soyoung Jeon(Yonsei University), Hye Sun Lee(Yonsei University)
International Journal of Radiation Oncology*Biology*Physics
August 22, 2022
Cited by 14
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
|BMC Cancer|2012|308
Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
|BMC Cancer|2019|267
Different prognostic value of white blood cell subtypes in patients with acute cerebral infarction
|Atherosclerosis|2012|243